We are live on ! Find out more
PSNL icon

Personalis

14.27 USD
-0.45
3.06%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
14.01
-0.26
1.82%
1 day
-3.06%
5 days
-8.53%
1 month
-10.48%
3 months
-15.46%
6 months
79.5%
Year to date
81.78%
1 year
72.34%
5 years
1.35%
10 years
-49.91%
 

About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Employees: 260

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 4%
Neutral 96%
Negative 0%
Positive
After Earnings
1 day ago
Tempus AI CEO Eric Lefkofsky on Cancer Data and the $1.5B Personalis Acquisition
Tempus AI ($TEM) Founder & CEO Eric Lefkofsky joins Austin Hankwitz on After Earnings to break down how Tempus is building one of the largest healthcare data businesses in the world, where AI is already changing patient care, and why he believes investors may be overlooking a significant part of the company's value. After Earnings is brought to you by Stakeholder Labs and Morning Brew.
Tempus AI CEO Eric Lefkofsky on Cancer Data and the $1.5B Personalis Acquisition
Neutral
GlobeNewsWire
4 days ago
PSNL Merger Investigation: Personalis Investigated Over $16.25 per Share Take-Private Merger – Contact BFA Law if You Hold Shares
NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc.   Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation.
PSNL Merger Investigation: Personalis Investigated Over $16.25 per Share Take-Private Merger – Contact BFA Law if You Hold Shares
Neutral
Business Wire
4 days ago
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Personalis, Inc. (NasdaqGM: PSNL) to Tempus AI, Inc. (NasdaqGS: TEM). Under the terms of the proposed transaction, shareholders of Personalis will receive $16.25 per common share. The consideration is reported to be structured as a 100% stock transaction, with Tempus having the option to elect p.
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
Neutral
GlobeNewsWire
11 days ago
PSNL Securities Notice: Personalis Shareholders are Notified to Contact BFA Law about its Investigation into the $16.25 per Share Take-Private Merger
NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc.   Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation.
PSNL Securities Notice: Personalis Shareholders are Notified to Contact BFA Law about its Investigation into the $16.25 per Share Take-Private Merger
Neutral
GlobeNewsWire
13 days ago
PERSONALIS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Personalis, Inc.'s Directors and Officers for Breach of Fiduciary Duties – PSNL
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Personalis, Inc. (NASDAQ: PSNL) approved a buyout of Personalis for inadequate consideration, breaching their fiduciary duties to Personalis's shareholders, and whether Personalis's shareholders have suffered damages as a result. Attorney Joseph A.
PERSONALIS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Personalis, Inc.'s Directors and Officers for Breach of Fiduciary Duties – PSNL
Neutral
GlobeNewsWire
13 days ago
PSNL Deal Alert: Personalis $16.25 per Share Merger Under Investigation – Contact BFA Law about the Pending Merger Investigation
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc.   Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation.
PSNL Deal Alert: Personalis $16.25 per Share Merger Under Investigation – Contact BFA Law about the Pending Merger Investigation
Neutral
GlobeNewsWire
16 days ago
PSNL Investigation Reminder: Personalis Shareholders Notified of Investigation into $16.25 per Share Merger – Contact BFA Law
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc.   Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation.
PSNL Investigation Reminder: Personalis Shareholders Notified of Investigation into $16.25 per Share Merger – Contact BFA Law
Neutral
Business Wire
17 days ago
Personalis Reports Third Quarter Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the third quarter ended September 30, 2026. Recent Strategic and Operational Highlights Launched NeXT Personal® Real-Time Variant Tracker™: Commercially launched optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report, which identify clinically relevant resis.
Personalis Reports Third Quarter Results
Neutral
GlobeNewsWire
18 days ago
PSNL Investigation Reminder: Personalis $16.25 per Share Merger Triggers Investigation on Behalf of Shareholders – Contact BFA Law if You Hold Shares
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation.
PSNL Investigation Reminder: Personalis $16.25 per Share Merger Triggers Investigation on Behalf of Shareholders – Contact BFA Law if You Hold Shares
Neutral
PRNewsWire
19 days ago
PSNL Shareholder Notice: Personalis $16.25 per Share Merger Under Investigation on Behalf of Shareholders
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders are notified to contact the firm. NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP  announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc.  Personalis is incorporated in Delaware.
PSNL Shareholder Notice: Personalis $16.25 per Share Merger Under Investigation on Behalf of Shareholders
Price charts implemented using Lightweight Charts™